Short revision bullets only, not a replacement for the full lesson sections below.
Toggle for a short revision list before a mock or question block.
Pathophysiology
Clinical meaning
Antisynthetase syndrome (ASS) is a systemic autoimmune disorder characterized by the triad of inflammatory myopathy (myositis), interstitial lung disease (ILD), and non-erosive arthritis, occurring in the context of autoantibodies directed against aminoacyl-tRNA synthetases. These enzymes catalyze the attachment of specific amino acids to their corresponding transfer RNA (tRNA) molecules, a critical step in protein synthesis. The syndrome represents one of the most clinically significant subsets of idiopathic inflammatory myopathies because of its distinctive clinical features, specific autoantibody associations, and the prominence of interstitial lung disease, which is the leading cause of morbidity and mortality.
Aminoacyl-tRNA synthetases (ARSs) are a family of 20 enzymes, each specific to one of the 20 standard amino acids. In antisynthetase syndrome, the immune system generates autoantibodies against one or more of these enzymes. The most common and best-characterized antisynthetase antibody is anti-Jo-1 (anti-histidyl-tRNA synthetase), which accounts for 60-80% of antisynthetase syndrome cases. Other identified antisynthetase antibodies include anti-PL-7 (anti-threonyl-tRNA synthetase), anti-PL-12 (anti-alanyl-tRNA synthetase), anti-EJ (anti-glycyl-tRNA synthetase), anti-OJ (anti-isoleucyl-tRNA synthetase), anti-KS (anti-asparaginyl-tRNA synthetase), anti-Zo (anti-phenylalanyl-tRNA synthetase), and anti-Ha/YRS (anti-tyrosyl-tRNA synthetase). Each antibody is associated with slightly different clinical phenotypes: anti-Jo-1 is associated with the most balanced presentation of myositis, ILD, and arthritis, while anti-PL-7 and anti-PL-12 are more strongly associated with ILD-predominant disease with less prominent myositis.
The immunopathogenesis involves both humoral and cell-mediated autoimmunity. Environmental triggers, particularly respiratory infections or lung injury, may expose intracellular aminoacyl-tRNA synthetases to the immune system. ARSs have been shown to have extracellular functions beyond protein synthesis: they can act as chemokines, attracting immune cells, and can be released from damaged cells during tissue injury. It is hypothesized that viral infection or pulmonary damage releases ARSs, which are then taken up and processed by antigen-presenting cells, leading to activation of autoreactive T-cells and B-cells in genetically susceptible individuals (particularly those with certain HLA-DRB1 alleles).
The muscle disease in antisynthetase syndrome is an inflammatory myopathy characterized histologically by perimysial inflammation (inflammation around the connective tissue sheaths surrounding muscle fascicles) with perifascicular necrosis (necrosis of muscle fibers at the periphery of fascicles). This pattern differs from the endomysial CD8+ T-cell infiltrates seen in inclusion body myositis and the perifascicular atrophy seen in dermatomyositis. The inflammatory infiltrate consists predominantly of CD4+ T-cells, macrophages, and dendritic cells that release pro-inflammatory cytokines (TNF-alpha, IL-1, IFN-gamma) causing direct myofiber damage and impaired muscle regeneration. Clinically, the myositis presents as symmetric proximal muscle weakness (difficulty rising from chairs, climbing stairs, raising arms above the head) with elevated serum creatine kinase (CK) levels, typically 5-50 times the upper limit of normal.
The interstitial lung disease in antisynthetase syndrome is the most clinically significant manifestation because it determines long-term prognosis and is the leading cause of death. The histopathological pattern is most commonly nonspecific interstitial pneumonia (NSIP), followed by organizing pneumonia (OP, formerly called BOOP), usual interstitial pneumonia (UIP), and diffuse alveolar damage (DAD). The lung inflammation involves both the alveolar epithelium and the pulmonary interstitium, with inflammatory cell infiltration, fibroblast proliferation, and progressive fibrosis. The ILD may be the presenting manifestation of antisynthetase syndrome (preceding myositis by months or years in up to 30% of cases), may occur simultaneously with myositis, or may develop years after the initial myositis diagnosis. High-resolution CT (HRCT) of the chest characteristically shows bilateral ground-glass opacities and consolidation (in NSIP/OP patterns) or honeycombing and traction bronchiectasis (in UIP pattern, which carries a worse prognosis).
The characteristic skin finding in antisynthetase syndrome is mechanic's hands -- hyperkeratotic, fissured, roughened skin on the lateral and palmar surfaces of the fingers and hands, resembling the hands of a manual laborer. This finding is present in 30-70% of antisynthetase syndrome patients and is nearly pathognomonic when present in combination with myositis and ILD. Additional features include Raynaud phenomenon (30-40% of patients), arthritis (typically non-erosive, affecting the small joints of the hands), fever (often the presenting symptom, sometimes occurring in a relapsing pattern), and constitutional symptoms (weight loss, fatigue).
Diagnosis is confirmed by detection of an antisynthetase antibody (anti-Jo-1 is available in most laboratories; other antibodies may require specialized reference laboratories) in the context of compatible clinical features. The modified Connors criteria or the Solomon criteria are used for classification. Treatment requires a multidisciplinary approach addressing both myositis and ILD: corticosteroids (prednisone 1 mg/kg/day) for initial disease control, followed by steroid-sparing immunosuppressive agents (azathioprine, mycophenolate mofetil, methotrexate, or tacrolimus) for long-term management. Rituximab is used for refractory disease, particularly refractory ILD. The prognosis depends primarily on the severity and progression of ILD: patients with NSIP or OP patterns have better outcomes than those with UIP pattern, and early aggressive immunosuppression may prevent progression to fibrosis.
Exam Focus
Exam relevance
Risk factors:
- Female sex (female-to-male ratio approximately 2:1; higher predominance in anti-PL-7 and anti-PL-12 subsets)
- Age of onset typically between 40-60 years (although antisynthetase syndrome can occur at any age, including childhood)
- HLA-DRB1 genetic susceptibility: certain HLA alleles (particularly HLA-DRB1*0301) are strongly associated with anti-Jo-1 antibody production
- Environmental triggers: respiratory infections, occupational dust or chemical exposure, and cigarette smoking may trigger or worsen ILD in genetically susceptible individuals
- African American race (higher incidence and more severe ILD compared to Caucasian patients)
- Presence of anti-PL-7, anti-PL-12, or anti-MDA5 antibodies (associated with more severe and treatment-resistant ILD compared to anti-Jo-1)
- Delayed diagnosis and treatment (ILD progression continues during the diagnostic delay, leading to irreversible pulmonary fibrosis)
Diagnostics:
- Antisynthetase antibody panel: anti-Jo-1 (most common, 60-80%), anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS; send to reference laboratory if standard panel is negative but clinical suspicion remains high; each antibody is associated with distinct clinical phenotypes
- Serum creatine kinase (CK): elevated 5-50 times the upper limit of normal in active myositis; CK levels correlate with disease activity and guide treatment response; may be normal in ILD-predominant disease without clinical myositis
- High-resolution CT (HRCT) chest: bilateral ground-glass opacities and consolidation (NSIP/OP patterns) or honeycombing with traction bronchiectasis (UIP pattern); HRCT pattern influences prognosis and treatment decisions
- Pulmonary function tests (PFTs): restrictive pattern with reduced FVC and reduced diffusing capacity for carbon monoxide (DLCO); DLCO is the most sensitive PFT parameter and may be abnormal even when FVC is preserved; serial PFTs monitor progression
- Muscle biopsy (when myositis is present): perimysial inflammation with perifascicular necrosis; distinguishes antisynthetase myopathy from other inflammatory myopathies; may not be necessary if antibody and CK are clearly diagnostic
- MRI of proximal muscles (thighs, upper arms): shows edema and inflammation in affected muscle groups on STIR sequences; useful for identifying active myositis and guiding biopsy site selection; also identifies fatty replacement indicating chronic damage
Core concept
Additional clinical detail, exam hooks, and takeaways continue in the full lesson.
Clinical scenario
Additional clinical detail, exam hooks, and takeaways continue in the full lesson.
Takeaways
Additional clinical detail, exam hooks, and takeaways continue in the full lesson.
Unlock full lesson + practice questions
3 more sections with scenarios, priorities, and review drills.
We didn’t match sample stems to this lesson in the bank yet. You can still run a topic-scoped drill with the same pathway filters—items load from your live NCLEX-RN pool.
